Neurocrine Presents P-III Studies (KINECT 3 & 4) Results of Ingrezza (valbenazine) for Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at SIRS 2023
Shots:
- The post hoc analysis results from P-III studies evaluating TD improvement & stability of psychiatric symptoms of Ingrezza (40 & 80mg) in 234 & 163 patients. Patients who were unable to tolerate 80mg dosage were permitted a dose decrease to 40mg
- The results showed that ≥90% of patients treated with Ingrezza (VMAT2 inhibitor) had a clinician-reported (CGI-TD - 94.3%) or patient-reported (PGIC = 91.9%) rating of "minimally improved" or better @48wk.
- ≥75% had global improvements as indicated by CGI-TD (79.7%) or PGIC (78.0%) ratings of "much improved" or better, -0.5 & -3.2 mean change from baseline to 48wk. in CDSS & PANSS total score with stability across subscales in PANSS total score & the results were consistent with prior studies
Ref: PRNewswire | Image: Neurocrine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
